CDP-choline and citicoline are the same compound.

Evidence at a glance

If a page on this site starts a sentence with either name, the first mention on that page still spells out citicoline (CDP-choline).

What citicoline is · Cognizin · Side effects

A closer reading

One molecule, two names

Citicoline (CDP-choline) is a single compound with two widely used names. This is not a marketing trick and it is not two separate products. "CDP-choline" is the biochemical name, short for cytidine diphosphate-choline. "Citicoline" is the name that appears on many supplement bottles and in many research papers. If you see one name in a journal article and the other on a label, you are reading about the same molecule.

This matters more than it might seem. People searching for information often assume the two names refer to different supplements, and then they go looking for two evidence bases that do not exist. There is one compound, one body of research, and one safety record. This page exists to settle that question and nothing else.

What the name CDP-choline actually means

Breaking the name apart helps explain why both terms exist.

Cytidine diphosphate-choline describes how the molecule is built. It has a cytidine part, which is related to one of the building blocks of RNA, and a choline part, joined together by a phosphate bridge. Chemists and biochemists tend to use "CDP-choline" because it names the structure directly. That is the name you will often see in older pharmacology papers and in basic-science research.

"Citicoline" became the common name in clinical medicine and, later, in the supplement market. Drug labels, clinical trial reports, and store shelves more often use "citicoline" because it is shorter and easier to read than the full chemical name.

Neither name is more correct. They are two labels for one thing, much like a person having a full legal name and a short everyday name.

Why the two-name problem confuses research reading

When you look up citicoline research, you will find papers that use either name, sometimes both in the same article. A few practical points follow from that:

The evidence does not split in two. Trials of "CDP-choline" and trials of "citicoline" are trials of the same compound. When this site reports a trial, the name in the original paper does not change what was studied.

The negative results apply to both names too. This is where the naming question becomes genuinely important. If someone tells you that "citicoline" failed in a major stroke trial but "CDP-choline" is different, that claim is wrong by definition. The largest stroke trial, ICTUS, published in The Lancet in 2012 with about 2,300 participants, found no improvement in 90-day recovery versus placebo. Earlier meta-analyses had suggested benefit, but the largest trial did not confirm that. Because both names mean the same compound, that result applies no matter which word is on the bottle. You can read the condition-by-condition record on the evidence hub.

Brand names do not create new molecules either. Cognizin is a brand of citicoline, which is CDP-choline. A branded ingredient is the same compound with quality controls and a trademark attached, not a different chemical. Some of the small positive trials, including attention studies in healthy women and in adolescent males, used Cognizin and were funded by its maker. That funding is worth knowing when you weigh those results, but the molecule tested is still citicoline (CDP-choline). More detail lives on the Cognizin page.

What the shared evidence actually looks like

Because there is one compound, there is one evidence base, and it is mixed. Naming clarity means taking the whole record at once, not just the flattering parts.

Stroke. As noted above, the largest trial found no benefit for 90-day recovery versus placebo. Earlier, smaller analyses pointed in a more hopeful direction, but they were not confirmed at scale. Citicoline is not a stroke treatment. Sudden facial droop, arm weakness, or speech difficulty can be a stroke. Call 911 immediately.

Traumatic brain injury. The COBRIT trial, published in JAMA in 2012, found that citicoline did not improve functional or cognitive outcomes versus placebo. This is a large, well-run negative trial, and it belongs in any honest summary.

Age-related cognitive decline. A Cochrane review of chronic cerebrovascular cognitive decline found modest short-term benefit on memory and behaviour, but the trials were short and of low quality. An observational study called IDEALE, in mild vascular cognitive impairment, found an association between citicoline use and stable scores compared with decline in an untreated group. Observational findings are weaker than trial findings and cannot prove cause.

Attention in healthy people. Two small industry-funded trials found better attention-test scores, one in healthy adult women and one in adolescent males. These are early signals, not established effects.

Glaucoma. Small trials have reported changes in electrophysiological measures when citicoline was used alongside standard treatment. Whether that translates into slower vision loss has not been established. See citicoline and glaucoma.

ADHD. There are no adequate trials. There is no good evidence that citicoline treats ADHD, whatever name a website uses. See citicoline and ADHD.

Mechanism. Evidence suggests citicoline supports membrane phospholipid synthesis, which is why researchers became interested in it in the first place. Stronger neuroprotection claims are preclinical only, meaning they come from laboratory and animal work, not from confirmed results in people.

None of these findings change depending on whether a source says "citicoline" or "CDP-choline."

How to use the name question in real life

Reading a label. If your bottle says CDP-choline, you have citicoline. If it says citicoline, you have CDP-choline. Check the dose per serving rather than worrying about which word appears. The supplement guide covers label reading in more depth.

Talking to your doctor. Either name works. Saying "citicoline, also called CDP-choline" in one sentence removes any ambiguity. Bringing the actual bottle, with the dose visible, is even better. The page on questions to ask your doctor can help you prepare.

Comparing supplements. Citicoline is sometimes compared with other choline sources, such as alpha-GPC. Those are genuinely different compounds, unlike the citicoline/CDP-choline pair. If a comparison seems to pit "citicoline" against "CDP-choline," it is comparing a compound to itself. The comparison page covers real head-to-head questions.

Reading this site. Every page spells out "citicoline (CDP-choline)" at first mention so that whichever name you searched for, you land on the same answer. After the first mention, pages may use either name. Nothing about the content changes with the word choice.

Safety is shared too

The safety record belongs to the compound, not to a name. In trials, citicoline has generally been well tolerated at doses of 250 to 2,000 mg per day. Reported side effects are usually mild: stomach upset, headache, and insomnia. Data in pregnancy and breastfeeding are lacking, so caution is the reasonable default there.

One interaction is worth flagging: citicoline may enhance the effects of levodopa, so people with Parkinson's disease should involve their neurologist before taking it. Full details are on the side-effects page and the dosage page, which report what studies recorded rather than offering anyone a personal dose.

In the United States, citicoline is sold as a dietary supplement, not as an FDA-approved drug. That status is the same regardless of what the label calls it.

What this page does not do

This page answers the naming question and stops there. It does not repeat the full benefit record, which lives on the evidence hub and its condition pages, including citicoline and memory. It does not tell you which product to buy; that kind of guidance, without recommendations of specific brands, is on how to choose a supplement. And it does not repeat the safety details beyond the summary above.

If you arrived here wondering whether you needed to research two different supplements, you can stop researching one of them. There is one compound, one evidence base with real negative trials in it, and one safety profile. The rest of this site is organized around that single compound, starting with what citicoline is.